Death by stress: Natural IgM-induced apoptosis

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 27, Issue 3, 2005, Pages 185-191

  Vollmers, H Peter ^a   Brandlein S ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Apoptosis; Immune surveillance; Innate immunity; Natural antibodies

Indexed keywords

ANTIBODY; ANTIBODY SC 1; DEATH RECEPTOR; DECAY ACCELERATING FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GROWTH FACTOR; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL; CANCER GROWTH; CELL DEATH; CELL ISOLATION; HUMAN; HYBRIDOMA; IMMUNOSURVEILLANCE; INNATE IMMUNITY; REVIEW; STRESS; SYSTEMATIC REVIEW;

EID: 17644427021     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2005.27.3.890876     Document Type: Review

References (77)

1. Miwa, T., Song, W.C. Membrane complement regulatory proteins: Insight from animal studies and relevance to human diseases. Int Immunopharmacol 2001, 1: 445-59.
2. Kerr, J.F., Wyllie, A.H., Currie, A.R. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972, 26: 239.
3. Van Cruchten, S., van den Broeck, W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol 2002, 31: 214-23.
4. Nagata, S. Fas and Fas ligand: A death factor and its receptor. Adv Immunol 1994, 57: 129-44.
5. Kitson, J., Raven, T., Jiang, Y.P. et al. A death-domain-containing receptor that mediates apoptosis. Nature 1996, 384: 372-5.
6. Nagata, S. Fas ligand-induced apoptosis. Annu Rev Genet 1999, 33: 29-55.
7. Curtin, J.F., Cotter, T.G. Live and let die: Regulatory mechanisms in Fas-mediated apoptosis. Cell Signal 2003, 15: 983-92.
8. Liu, X., Kim, C.N., Yang, J., Jemmerson, R., Wang, X. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c. Cell 1996, 86: 147-57.
9. Li, P., Nijhawan, D., Budihardjo, I. et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91: 479-89.
10. Reed, J.C. Double identity for proteins of the Bcl-2 family. Nature 1997, 387: 773-6.
11. Slater, A.F., Stefan, C., Nobel, I., van den Dobbelsteen, D.J., Orrenius, S. Signalling mechanisms and oxidative stress in apoptosis. Toxicol Lett 1995, 82-83: 149-53.
12. Bosca, L., Hortelano, S. Mechanisms of nitric oxide-dependent apoptosis: Involvement of mitochondrial mediators. Cell Signal 1999, 11: 239-44.
13. Ferri, K.F., Kroemer, G. Organelle-specific initiation of cell death pathways. Nat Cell Biol 2001, 3: 255-63.
14. Boes, M. Role of natural and immune IgM antibodies in immune responses. Mol Immunol 2000, 37: 1141-9.
15. Brändlein, S., Pohle, T., Ruoff, N. et al. Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res 2003, 63: 7995-8005.
16. Littlefield, J. Selection of hybrids from matings of fibroblasts in vitro and their presumed recombinants. Science 1964, 145: 709-11.
17. Littlefield, J.W. The use of drug-resistant markers to study the hybridization of mouse fibroblasts. Exp Cell Res 1966, 41: 190-6.
18. Kohler, G., Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256: 495-7.
19. Galfre, G., Howe, S.C., Milstein, C., Butcher, G.W., Howard, J.C. Antibodies to major histocompatibility antigens produced by hybrid cell lines. Nature 1977, 266: 550-2.
20. Dunbar, B.S., Skinner, S.M. Preparation of monoclonal antibodies. Methods Enzymol 1990, 182: 670-9.
21. von Mehren, M., Weiner, L.M. Monoclonal antibody-based therapy. Curr Opin Oncol 1996, 8: 493-8.
22. Dickman, S. Antibodies stage a comeback in cancer treatment. Science 1998, 280: 1196-7.
23. McNeil, C. Monoclonal antibodies progress to the next generation. J Natl Cancer Inst 1995, 87: 1738-9.
24. Hall, S.S. Monoclonal antibodies at age 20: Promise at last? Science 1995, 270: 915-6.
25. Houghton, A.N., Scheinberg, D.A. Monoclonal antibody therapies - a 'constant' threat to cancer. Nat Med. 2000, 6: 373-4.
26. Vollmers, H.P., O'Connor, R., Müller, J., Kirchner, T., Müller-Hermelink, H.K. SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells. Cancer Res 1989, 49: 2471-6.
27. Brändlein, S., Lorenz, J., Ruoff, N. et al. Human monoclonal IgM antibodies with apoptotic activity isolated from cancer patients. Hum Antibodies 2002, 11: 107-19.
28. Pohle, T., Brändlein, S., Ruoff, N., Müller-Hermelink, H.K., Vollmers, H.P. Lipoptosis: tumor-specific cell death by antibody-induced intracellular lipid accumulation. Cancer Res 2004, 64: 3900-6.
29. Brändlein, S., Vollmers, H.P. Natural IgM antibodies, the ignored weapons in tumour immunity. Histol Histopathol 2004, 19: 897-905.
30. Hensel, F., Hermann, R., Schubert, C. et al. Characterisation of glycosylphosphatidyl-inositol-linked molecule CD55/decay-accelerating factor as the receptor for antibody SC-1-induced apoptosis. Cancer Res 1999, 59: 5299-306.
31. Hensel, F., Hermann, R., Brandlein, S. et al. Regulation of the new coexpressed CD55 (decay-accelerating factor) receptor on stomach carcinoma cells involved in antibody SC-1-induced apoptosis. Lab Invest 2001, 81: 1553-63.
32. Hensel, F., Brandlein, S., Eck, M. et al. A novel proliferation- associated variant of CFR-1 defined by a human monoclonal antibody. Lab Invest 2001, 81: 1097-108.
33. Brändlein, S., Pohle, T., Vollmers, C. et al. CFK-1 receptor as target for tumor-specific apoptosis induced by the natural human monoclonal antibody PAM-1. Oncol Rep 2004, 11: 777-84.
34. Trauth, B.C., Klas, C., Peters, A.M. et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989, 245: 301-5.
35. Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M. et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993, 364: 806-9.
36. Nagata, S. Apoptosis by death factor. Cell 1997, 88: 355-65.
37. Ichikawa, K., Liu, W., Zhao, L. et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001, 7: 954-60.
38. Hu, W., Kavanagh, J.J. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 2003, 4: 721-9.
39. Jo, M., Kim, T.H., Seol, D.W. et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000, 6: 564-7.
40. Scaffidi, C., Fulda, S., Srinivasan, A. et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998, 17: 1675-87.
41. Findley, H.W., Zhou, M. The clinical significance of Fas expression in leukemia: Questions and controversies. Leukemia 1999, 13: 147-9.
42. Maloney, D.G., Grillo-Lopez, A.J., Bodkin, D.J. et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997, 15: 3266-74.
43. Cheson, B.D. Hematologic malignancies: New developments and future treatments. Semin Oncol 2002, 29: 33-45.
44. Ludwig, D.L., Pereira, D.S., Zhu, Z., Hicklin, D.J., Bohlen, P. Monoclonal antibody therapeutics and apoptosis. Oncogene 2003, 22: 9097-106.
45. McKeage, K., Perry, C.M. Trastuzumab: A review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002, 62: 209-43.
46. Sato, J.D., Kawamoto, T., Le, A.D., Mendelsohn, J., Polikoff, J., Sato, G.H. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983, 1: 511-29.
47. Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents. J Steroid Biochem Mol Biol 1990, 37: 889-92.
48. Mendelsohn, S. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997, 3: 2703-7.
49. Mendelsohn, J., Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19: 6550-65.
50. Huang, S.M., Harari, P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000, 6: 2166-74.
51. Goodman, G.E., Hellstrom, I., Brodzinsky, L. et al. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol 1990, 8: 1083-92.
52. Valerius, T., Stockmeyer, B., van Spriel, A.B. et al. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood 1997, 90: 4485-92.
53. Shan, D., Ledbetter, J.A., Press, O.W. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000, 48: 673-83.
54. Ghetie, M.A., Bright, H., Vitetta, E.S. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001, 97: 1392-8.
55. Cardarelli, P.M., Quinn, M., Buckman, D. et al. Binding to CD20 by anti-B1 antibody or F(ab′)(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002, 51: 15-24.
56. van der Kolk, L.E., Evers, L.M., Omene, C. et al. CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia 2002, 16: 1735-44.
57. Carter, P., Presta, L., Gorman, C.M. et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992, 89: 4285-9.
58. Penuel, E., Schaefer, G., Akita, R.W., Sliwkowski, M.X. Structural requirements for ErbB2 transactivation. Semin Oncol 2001, 28: 36-42.
59. Pietras, R.J., Poen, J.C., Gallardo, D., Wongvipat, P.N., Lee, H.J., Slamon, D.J. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999, 59: 1347-55.
60. Yakes, P.M., Chinratanalab, W., Ritter, C.A., King, W., Seelig, S., Arteaga, C.L. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cydin D1, and antitumor action. Cancer Res 2002, 62: 4132-41.
61. Dougall, W.C., Greene, M.I. Biological studies and potential therapeutic applications of monoclonal antibodies and small molecules reactive with the neu/c-erbB-2 protein. Cell Biophys 1994, 24(25): 209-18.
62. Alimandi, M., Romano, A., Curia, M.C. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995, 10: 1813-21.
63. Vollmers, H.P., Dämmrich, J., Ribbert, H., Wozniak, E., Müller-Hermelink, H.K. Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody. Cancer 1995, 76: 550-8.
64. Ollert M.W., David K., Schmitt C. et al. Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells. Proc Natl Acad Sci U S A 1996, 93: 4498-503.
65. David K., Ollert M.W., Vollmert C. et al. Human natural immunoglobulin M antibodies induce apoptosis of human neuroblastoma cells by binding to a Mr 260,000 antigen. Cancer Res 1999, 59: 3768-75.
66. Narula, J., Pandey, P., Arbustini, E. et al. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci U S A 1999, 96: 8144-9.
67. Kang, P.M., Izumo, S. Apoptosis and heart failure: A critical review of the literature. Circ Res 2000, 86: 1107-13.
68. Davis, L.S., Patel, S.S., Atkinson, J.P., Lipsky, P.E. Decay-accelerating factor functions as a signal transducing molecule for human T cells. J Immunol 1988, 141: 2246-52.
69. Kuraya, M., Fujita, T. Signal transduction via a protein associated with a glycosylphosphatidylinositol-anchored protein, decay-accelerating factor (DAF/CD55). Int Immunol 1998, 10: 473-80.
70. Caras, I.W., Davitz, M.A., Rhee, L., Weddell, G., Martin, D.W.J., Nussenzweig, V. Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature 1987, 325: 545-9.
71. Vollmers, H.P., Dämmrich, J., Hensel, F. et al. Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma. Cancer 1997, 79: 433-40.
72. Vollmers, H.P., Hensel, F., Hermann, R. et al. Tumor-specific apoptosis by the human monoclonal antibody SC-1: A new therapeutical approach for stomach cancer. Oncol Rep 1998, 5: 35-40.
73. Vollmers, H.P., Zimmermann, U., Krenn, V. et al. Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: First clinical and histopathological results. Oncol Rep 1998, 5: 549-52.
74. Hermann, R., Hensel, F., Muller, E.C. et al. Deactivation of regulatory proteins hnRNP A1 and A2 during SC-1 induced apoptosis. Hum Antibodies 2001, 10: 83-90.
75. Vollmers, H.P., Dämmrich, J., Ribbert, H. et al. Human monoclonal antibodies from stomach carcinoma patients react with Helicobacter pylori and stimulate stomach cancer cells in vitro. Cancer 1994, 74: 1525-32.
76. Burrus, L.W., Zuber, M.E., Lueddecke, B.A., Olwin, B.B. Identification of a cysteine-rich receptor for fibroblast growth factors. Mol Cell Biol 1992, 12: 5600-9.
77. Brändlein S., Beyer I., Eck, M. et al. CFR-1, a new marker for precancerous epithelial lesions defined by the human monoclonal antibody PAM-1. Cancer Res 2003, 63: 2052-61.